^
Association details:
| Biomarker: | KRAS mutation + YKL-40 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2465 / 5 - YKL-40 overexpression enhances metastatic potential and is a novel prognostic candidate and predictive biomarker for patients with colorectal cancer
Published date:
03/15/2023
Excerpt:
Six independent cohorts of CRC patients were stratified by YKL-40 tissue expression to define its prognostic role and its effect on cetuximab and oxaliplatin treatment response....YKL-40 high tissue levels showed a predictive value for better response to cetuximab, even in patients with stage IV CRC and mutant KRAS...
Source:
Title:
Upregulation of YKL-40 Promotes Metastatic Phenotype and Correlates with Poor Prognosis and Therapy Response in Patients with Colorectal Cancer
Published date:
11/11/2022
Excerpt:
Strikingly, high YKL-40 tissue levels showed a predictive value for a better response to cetuximab, even in patients with stage IV CRC and mutant KRAS...KRAS-mutant patients with YKL-40high showed a significantly longer PFS duration...Finally, we evaluated the role of the YKL-40 expression level in the response to oxaliplatin therapy. In this case, significantly shorter survival (OS) was associated with elevated YKL-40 gene expression.
DOI:
10.3390/cells11223568
